AB Science Completes Capital Increases Totaling EUR 14.2 Million
AB Science has successfully completed capital increases totaling EUR 14.2 million in gross proceeds. The funds are designated to finance the company's clinical programs.
Biotechnology company AB Science announced the successful completion of capital increases that raised a total gross amount of EUR 14.2 million. The company stated that the proceeds will be used to finance its ongoing clinical programs.
AB Science is developing masitinib, a potential new therapeutic agent, for various indications including Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), COVID-19, and certain cancers. The company is also advancing AB8939, a compound targeting hematological cancers.
The successful fundraising effort is intended to support the continued research and clinical trials for these drug candidates, aiming to advance them toward regulatory approval and market launch.